Original article by Julia Medew
The Age – Page: 13 : 5-Dec-14

Some 300 Australians annually, or 5% of all who are suffering from lung cancer, can benefit substantially from Pfizer’s Crizotinib drug. It can boost the life expectancy of the patients, which is especially important as the non-small cell lung cancer variant tends to affect young people more. However the cost of the treatment is $A90,000 per year, and the Federal Government may not approve the drug for subsidies under the pharmaceutical benefits scheme in late 2014

CORPORATES
AUSTRALIA. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE, PFIZER PTY LTD, PETER MACCALLUM CANCER INSTITUTE